CHARLES SCHWAB INVESTMENT MANAGEMENT INC - LYELL IMMUNOPHARMA INC ownership

LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 106 filers reported holding LYELL IMMUNOPHARMA INC in Q3 2023. The put-call ratio across all filers is 0.22 and the average weighting 0.5%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of LYELL IMMUNOPHARMA INC
ValueSharesWeighting
Q3 2023$1,838,545
-49.8%
1,250,711
+8.6%
0.00%0.0%
Q2 2023$3,663,389
+36.2%
1,152,009
+1.1%
0.00%0.0%
Q1 2023$2,689,159
-31.6%
1,139,474
+0.6%
0.00%0.0%
Q4 2022$3,931,010
-51.8%
1,132,856
+1.9%
0.00%
-66.7%
Q3 2022$8,152,000
+155.5%
1,112,110
+127.3%
0.00%
+200.0%
Q2 2022$3,190,000
+39.4%
489,207
+8.0%
0.00%0.0%
Q1 2022$2,289,000
+72.6%
453,144
+164.7%
0.00%
Q4 2021$1,326,000
-46.1%
171,206
+3.0%
0.00%
-100.0%
Q3 2021$2,461,000166,2550.00%
Other shareholders
LYELL IMMUNOPHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
MWG Management Ltd. 20,162,332$131,458,00059.13%
Apoletto Ltd 15,093,969$98,413,00027.22%
Foresite Capital Management IV, LLC 13,282,181$86,600,00023.32%
MIC Capital Management UK LLP 3,060,569$19,955,0003.90%
Alphabet Inc. 5,865,125$38,241,0002.08%
HSG Holding Ltd 3,045,997$19,860,0001.83%
Board of Trustees of The Leland Stanford Junior University 1,647,882$10,744,0000.72%
SG3 Management, LLC 600,000$3,912,0000.46%
KETTLE HILL CAPITAL MANAGEMENT, LLC 157,700$1,028,0000.26%
Artal Group S.A. 700,000$4,564,0000.24%
View complete list of LYELL IMMUNOPHARMA INC shareholders